H. Lundbeck AS (LTS:0ND5) Institutional Ownership : 7.86% (As of Jun. 10, 2024)

View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, H. Lundbeck AS's institutional ownership is 7.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, H. Lundbeck AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, H. Lundbeck AS's Float Percentage Of Total Shares Outstanding is 0.00%.

H. Lundbeck AS Institutional Ownership Historical Data

The historical data trend for H. Lundbeck AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Institutional Ownership Chart

H. Lundbeck AS Historical Data

The historical data trend for H. Lundbeck AS can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	7.88	8.02	7.96	8.32	8.30	8.25	7.96	7.86	7.90	7.86

H. Lundbeck AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

H. Lundbeck AS (LTS:0ND5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

HLBBF:USA HLUBF:USA 0ABR:UK HLUN A:Denmark HLUN B:Denmark LDBA:Germany

Address

Ottiliavej 9, Valby, DNK, 2500

Website

https://www.lundbeck.com

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines